A New Approach To the Management of Obliterative Peripheral Arterial Disease

Casten, Gus G.; Gilmore, Hugh R.; Houghton, F.E.; Samuels, Saul S.

doi:10.1177/000331976001100506

Cited by 25 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding confirms the notion that RLX is a more potent vasodilator of pre-constricted vessels, as it is also indicated by the earlier studies in rats [43][44][45] and by a previous largescale clinical trial in patients with systemic sclerosis [49,50]. In keeping with this observation, RLX reduced the need for nitrovasodilators to control high blood pressure, as also observed in the pioneering observations made by Casten and co-workers in 1960 using an impure porcine RLX preparation on cardiovascular patients [51]. As with other vasodilators, RLX treatment at any tested dose induced a slight decrease in haematocrit, closely concurrent with drug administration and of no clinical relevance.…”

Section: Relaxin As a Cardiovascular Drugsupporting

confidence: 66%

Relaxin as a Cardiovascular Drug: A Promise Kept

Bani¹,

Bigazzi

2011

CDS

View full text Add to dashboard Cite

Relaxin (RLX), formerly known for its effects on reproduction and pregnancy, has been later shown to be a pleiotropic hormone, capable of also targeting numerous non-reproductive organs of the cardiovascular, nervous, respiratory, tegumental, excretory and digestive systems. Most of these effects have been studied in animal models, but there is compelling evidence that RLX also acts in humans. In more recent years, human luteal-type (H2) RLX synthesised by recombinant DNA technology has been investigated in clinical trials, mostly oriented to assess its therapeutic potential in cardiovascular disease. This indication was based on the accumulating pre-clinical evidence that RLX possesses prominent biological effects on systemic and coronary blood vessels, cardiomyocyte growth and differentiation, and cardiac/vascular connective tissue remodelling. This mini-review was intended as an update of our previous article that appeared in this journal in 2009, as the last 2 years have been characterised by fundamental achievements on the clinical profile of RLX. Eventually, after many years of inconclusive studies, RLX appears to be about to reach a recognised dignity as a cardiovascular drug.

show abstract

Section: Relaxin As a Cardiovascular Drugsupporting

confidence: 66%

Relaxin as a Cardiovascular Drug: A Promise Kept

Bani¹,

Bigazzi

2011

CDS

View full text Add to dashboard Cite

show abstract

“…45 In addition, Casten et al used relaxin to treat patients having peripheral vascular disease, and demonstrated an impressive amelioration of peripheral arteriopathy and ischemic ulcers. 46 In a more recent study, the use of relaxin in patients with severe idiopathic occlusive peripheral artery disease of the lower limbs caused a marked longacting amelioration of both subjective symptoms and clinical signs. 47 These effects persisted even after discontinuation of the drug.…”

Section: Non-heart Failure Patientsmentioning

confidence: 98%

Relaxin

Grossman¹,

Frishman²

2010

Cardiology in Review

View full text Add to dashboard Cite

Relaxin, a naturally-occurring hormone in the insulin family, was discovered to have a physiologic role in pregnancy. Named initially for its relaxing effect on the pubic ligament, relaxin receptors have since been found to be widely distributed in many organs in both males and females. Acting through multiple pathways, including the stimulation of gelatinases leading to activation of endothelin type B receptors and subsequently nitric oxide, relaxin has been shown to cause vasodilation. In animal models and studies in humans, relaxin has been shown to increase cardiac output and renal perfusion. Due to these effects, relaxin has been examined as a treatment for acute heart failure. The results of phase I and II trials have shown favorable clinical trends without any major adverse events, suggesting that relaxin has the potential to be an effective medication for acute heart failure in conjunction with or in place of current treatments.

show abstract

“…Relaxin may also enhance wound healing through its proangiogenic effects. Relaxin was first thought to have angiogenic effects in the late 1950 s, when the clinical administration of impure porcine relaxin to patients with scleroderma and peripheral vascular disease resulted in healing of ischaemic ulcers on fingers and toes and improvement in peripheral vascular disease symptomology [114,115]. Although some of these effects may be attributable to the increase in blood supply as a result of vasodilation, relaxin also has direct effects on the angiogenic process.…”

Section: Wound Healing and Proangiogenic Effects Of Relaxinmentioning

confidence: 99%

Drugs of the future: the hormone relaxin

Samuel

Hewitson

Unemori

et al. 2007

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

The peptide hormone relaxin is emerging as a multi-functional factor in a broad range of target tissues including several non-reproductive organs, in addition to its historical role as a hormone of pregnancy. This review discusses the evidence that collectively demonstrates the many diverse and vital roles of relaxin: the homeostatic role of endogenous relaxin in mammalian pregnancy and ageing; its gender-related effects; the therapeutic effects of relaxin in the treatment of fibrosis, inflammation, cardioprotection, vasodilation and wound healing (angiogenesis) amongst other pathophysiological conditions, and its potential mechanism of action. Furthermore, translational issues using experimental models (to humans) and its use in various clinical trials, are described, each with important lessons for the design of future trials involving relaxin. The diverse physiological and pathological roles for relaxin have led to the search for its significance in humans and highlight its potential as a drug of the future.

show abstract

A New Approach To the Management of Obliterative Peripheral Arterial Disease

Cited by 25 publications

References 8 publications

Relaxin as a Cardiovascular Drug: A Promise Kept

Relaxin as a Cardiovascular Drug: A Promise Kept

Relaxin

Drugs of the future: the hormone relaxin

Contact Info

Product

Resources

About